Fig. 1: Consort diagram of patient flow.
From: Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Ten patients were enrolled in the study and underwent leukapheresis. Anti-CD7 CAR-T cells were derived from patients or their donors and infused into all patients at a low dose (1 × 106/kg, n = 5) or a high dose (2 × 106/kg, n = 5).
